NCT04181658

Brief Summary

This pilot work will determine the feasibility of tDCS intervention as an effective adjunct intervention to PT aimed at improving gait, balance, and mobility in older adults at risk of falling.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 22, 2019

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 26, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 29, 2019

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2021

Completed
Last Updated

September 5, 2021

Status Verified

September 1, 2021

Enrollment Period

1.5 years

First QC Date

November 26, 2019

Last Update Submit

September 1, 2021

Conditions

Outcome Measures

Primary Outcomes (7)

  • Screening to enrollment ratio (%, 0-100, higher ratio means a better outcome)

    The number of screenings needed to enroll one participant

    The whole data collection period (~ 6 months for the whole study)

  • Intervention adherence rate (%, 0-100, higher ratio means a better outcome)

    Number of tDCS sessions completed

    The whole data collection period (~ 6 months for the whole study)

  • Adherence rate (%, 0-100, higher ratio means a better outcome)

    The portion of enrolled participants who complete and adhere to the intervention who complete and adhere to the intervention

    The whole data collection period (~ 6 months for the whole study)

  • Side effects

    The number, type, severity and duration of reported side effects

    The whole data collection period (~ 6 months for the whole study)

  • Change from baseline in the dual task cost to gait speed (reduced dual task cost after intervention means a better outcome)

    The change from baseline in the degree to which performing a secondary cognitive task diminishes gait speed

    Before and after the intervention (~ 6 weeks per participant)

  • Change from baseline in the dual task cost to standing postural sway speed (reduced dual task cost after intervention means a better outcome)

    The change from baseline in the degree to which performing a secondary cognitive task diminishes the control of standing posture.

    Before and after the intervention (~ 6 weeks per participant)

  • Change from baseline in Trail Making Test B - A (reduced time after intervention means a better outcome)

    The change from baseline in cognitive executive function

    Before and after the intervention (~ 6 weeks per participant)

Secondary Outcomes (5)

  • Change from baseline in gait speed (increased value after intervention means a better outcome)

    Before and after the intervention (~ 6 weeks per participant)

  • Change from baseline in gait variability (reduced value after intervention means a better outcome)

    Before and after the intervention (~ 6 weeks per participant)

  • Change from baseline in gradual-onset continuous performance test (gradCPT) ( increased accuracy after intervention means a better outcome)

    Before and after the intervention (~ 6 weeks per participant)

  • Change from baseline in Timed Up-and-Go (TUG) (reduced time after intervention means a better outcome)

    Before and after the intervention (~ 6 weeks per participant)

  • Change from baseline in Montreal Cognitive Assessment (MoCA) total score (increased score after intervention means a better outcome)

    Before and after the intervention (~ 6 weeks per participant)

Study Arms (2)

Real tDCS and Physical Therapy

EXPERIMENTAL

This arm combines tDCS and Physical Therapy intervention. The real tDCS will be delivered before each physical therapy visit for up to 10 combined sessions. The tDCS montage was designed to target the left dorsal lateral prefrontal cortex (DLPFC) for around 20 minutes. The direct current delivered by any electrode will not exceed 2.0 milliamp(mA) and the total amount of current from all electrodes will not exceed 4 mA.

Other: Real tDCS and Physical Therapy

Sham stimulation and Physical Therapy

SHAM COMPARATOR

This arm combines sham stimulation and Physical Therapy intervention. The sham stimulation will be delivered before each physical therapy visit for up to 10 combined sessions. We will use an active sham stimulation in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This montage was designed to deliver currents not significantly influence their cortical tissue, but still, mimic the cutaneous sensations induced by tDCS over the same brain site (i.e. left DLPFC).

Other: Sham stimulation and Physical Therapy

Interventions

The participant will receive 20-minute sessions of real tDCS before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.

Also known as: Real tDCS + PT
Real tDCS and Physical Therapy

The participant will receive 20-minute sessions of sham stimulation before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.

Also known as: Sham stimulation + PT
Sham stimulation and Physical Therapy

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Ages 65 years old and above
  • Admitted to Physical Therapy for gait and balance training due to the high risk of falls

You may not qualify if:

  • Inability to stand or walk unassisted for 60 seconds
  • Severe cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score \< 18
  • Any unstable medical condition
  • Any unstable psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis
  • Active cancer for which chemo/radiation therapy id being received
  • Significant vision and hearing problems that cannot be corrected with visual and hearing aids
  • Contraindications to tDCS, including seizure within the past two years, use of neuro-active drugs, the risk of metal objects in the brain, implanted medical devices, or the presence of dermatological conditions such as eczema on the scalp.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hebrew Rehabilitation Center

Boston, Massachusetts, 02131, United States

Location

MeSH Terms

Conditions

Gait Disorders, Neurologic

Interventions

Physical Therapy Modalities

Condition Hierarchy (Ancestors)

Neurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

TherapeuticsRehabilitation

Study Officials

  • On-Yee Lo, PhD

    Hebrew Rehabilitation Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 26, 2019

First Posted

November 29, 2019

Study Start

October 22, 2019

Primary Completion

May 1, 2021

Study Completion

May 1, 2021

Last Updated

September 5, 2021

Record last verified: 2021-09

Locations